NCT06968312 Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD
| NCT ID | NCT06968312 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tel Aviv University |
| Condition | Post Traumatic Stress Disorder (PTSD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-05-05 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of PTSD according to DSM-5 * Age 18 years and over * Eligible for CPT treatment at the National Center for Traumatic Stress and Resilience Exclusion Criteria: * Bipolar disorder, psychosis, neurological disorders * Drug Addiction * Parallel psychotherapy * Congenital or acquired anosmia.
Contact & Investigator
Yair Bar Haim, PhD
PRINCIPAL INVESTIGATOR
Tel Aviv University
Frequently Asked Questions
Who can join the NCT06968312 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Post Traumatic Stress Disorder (PTSD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06968312 currently recruiting?
Yes, NCT06968312 is actively recruiting participants. Contact the research team at yair1@tauex.tau.ac.il for enrollment information.
Where is the NCT06968312 trial being conducted?
This trial is being conducted at Tel Aviv, Israel.
Who is sponsoring the NCT06968312 clinical trial?
NCT06968312 is sponsored by Tel Aviv University. The principal investigator is Yair Bar Haim, PhD at Tel Aviv University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.